Published in Trials on June 09, 2006
Chagas Cardiomyopathy Bisoprolol Intervention Study: Charity | NCT00323973
Diagnosis and management of Chagas disease and cardiomyopathy. Nat Rev Cardiol (2012) 1.45
Role of autoantibodies in the physiopathology of Chagas' disease. Arq Bras Cardiol (2008) 0.83
The future of implantable defibrillator and cardiac resynchronization therapy trials. J Interv Card Electrophysiol (2008) 0.75
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med (1996) 12.77
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet (1999) 11.26
Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med (2001) 7.05
Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J (2001) 5.77
Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet (2001) 4.65
Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. Circulation (1996) 4.01
Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise. Circulation (1996) 3.98
Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group. Circulation (1996) 3.14
Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J (1975) 2.71
A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees. Circulation (1994) 2.58
Survival and predictors of survival in patients with congestive heart failure due to Chagas' cardiomyopathy. Circulation (1994) 1.84
Prospective, randomized comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure. Circulation (1999) 1.59
Chagas' heart disease in the United States. N Engl J Med (1991) 1.56
Consensus recommendations for the management of chronic heart failure. On behalf of the membership of the advisory council to improve outcomes nationwide in heart failure. Am J Cardiol (1999) 1.48
Effects of carvedilol, a vasodilator-beta-blocker, in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group. Circulation (1995) 1.04
Chagas' heart disease. Curr Probl Cardiol (1995) 0.93
A cost-minimization of heart failure therapy with bisoprolol in the French setting: an analysis from CIBIS trial data. Cardiac Insufficiency Bisoprolol Study. Cardiovasc Drugs Ther (1998) 0.89
In vitro and in vivo characterization of intrinsic sympathomimetic activity in normal and heart failure rats. J Pharmacol Exp Ther (1999) 0.87
Chagas cardiomyopathy and captopril. Eur Heart J (1992) 0.84
Chronic Chagas' heart disease in children and adolescents: a clinicopathologic study. Int J Cardiol (1985) 0.78
Alteration of the pattern of beta-adrenergic desensitization in cultured L6E9 muscle cells infected with Trypanosoma cruzi. Mol Biochem Parasitol (1984) 0.78
Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature (2011) 13.25
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature (2011) 13.23
Subclinical atrial fibrillation and the risk of stroke. N Engl J Med (2012) 11.11
A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. Nat Genet (2010) 8.48
Genome-wide association analysis identifies 13 new risk loci for schizophrenia. Nat Genet (2013) 7.44
Approaches to catheter ablation for persistent atrial fibrillation. N Engl J Med (2015) 6.68
CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis. JAMA (2011) 5.93
Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility. Nat Genet (2011) 5.56
Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med (2014) 5.44
Genome-wide association study of ulcerative colitis identifies three new susceptibility loci, including the HNF4A region. Nat Genet (2009) 4.61
Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. Nat Genet (2010) 4.42
Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol (2005) 4.40
Chagas disease: an overview of clinical and epidemiological aspects. J Am Coll Cardiol (2013) 3.76
Discerning the incidence of symptomatic and asymptomatic episodes of atrial fibrillation before and after catheter ablation (DISCERN AF): a prospective, multicenter study. JAMA Intern Med (2013) 3.56
Genome-wide association study identifies a variant in HDAC9 associated with large vessel ischemic stroke. Nat Genet (2012) 3.40
Implantable cardioverter-defibrillator shock prevention does not reduce mortality: a systemic review. Heart Rhythm (2012) 2.65
Estimation of bias in nongenetic observational studies using "mendelian triangulation". Ann Epidemiol (2006) 2.57
Large-scale gene-centric meta-analysis across 39 studies identifies type 2 diabetes loci. Am J Hum Genet (2012) 2.53
Secretory phospholipase A(2)-IIA and cardiovascular disease: a mendelian randomization study. J Am Coll Cardiol (2013) 2.18
Meta-analysis of Dense Genecentric Association Studies Reveals Common and Uncommon Variants Associated with Height. Am J Hum Genet (2010) 2.15
Critical appraisal of CRP measurement for the prediction of coronary heart disease events: new data and systematic review of 31 prospective cohorts. Int J Epidemiol (2008) 2.14
Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas' cardiomyopathy: the BENznidazole Evaluation For Interrupting Trypanosomiasis (BENEFIT). Am Heart J (2008) 1.99
Large-scale gene-centric meta-analysis across 32 studies identifies multiple lipid loci. Am J Hum Genet (2012) 1.96
Inflammation, insulin resistance, and diabetes--Mendelian randomization using CRP haplotypes points upstream. PLoS Med (2008) 1.95
Association between genetic variants on chromosome 15q25 locus and objective measures of tobacco exposure. J Natl Cancer Inst (2012) 1.83
Cryptogenic Stroke and underlying Atrial Fibrillation (CRYSTAL AF): design and rationale. Am Heart J (2010) 1.76
Comparative analysis of genome-wide association studies signals for lipids, diabetes, and coronary heart disease: Cardiovascular Biomarker Genetics Collaboration. Eur Heart J (2011) 1.73
Statins for all by the age of 50 years? Lancet (2012) 1.69
Cost comparison of catheter ablation and medical therapy in atrial fibrillation. J Cardiovasc Electrophysiol (2007) 1.67
Tackling non-communicable diseases in low- and middle-income countries: is the evidence from high-income countries all we need? PLoS Med (2013) 1.67
Role of the implantable defibrillator among elderly patients with a history of life-threatening ventricular arrhythmias. Eur Heart J (2007) 1.63
A systematic review of randomized trials comparing radiofrequency ablation with antiarrhythmic medications in patients with atrial fibrillation. J Cardiovasc Electrophysiol (2008) 1.59
Congestive heart failure in Latin America: the next epidemic. Am Heart J (2004) 1.58
Major cardiovascular risk factors in Latin America: a comparison with the United States. The Latin American Consortium of Studies in Obesity (LASO). PLoS One (2013) 1.56
The BENEFIT trial: testing the hypothesis that trypanocidal therapy is beneficial for patients with chronic Chagas heart disease. Mem Inst Oswaldo Cruz (2009) 1.54
Canadian Registry of ICD Implant Testing procedures (CREDIT): current practice, risks, and costs of intraoperative defibrillation testing. J Cardiovasc Electrophysiol (2009) 1.53
Common variants at the MHC locus and at chromosome 16q24.1 predispose to Barrett's esophagus. Nat Genet (2012) 1.52
Age of first faint in patients with vasovagal syncope. J Cardiovasc Electrophysiol (2006) 1.52
Slow wall motion rather than electrical conduction delay underlies mechanical dyssynchrony in postinfarction patients with narrow QRS complex. J Cardiovasc Electrophysiol (2009) 1.50
Noncommunicable diseases and injuries in Latin America and the Caribbean: time for action. PLoS Med (2006) 1.49
Device-related infection among patients with pacemakers and implantable defibrillators: incidence, risk factors, and consequences. J Cardiovasc Electrophysiol (2010) 1.48
R-wave peak time at DII: a new criterion for differentiating between wide complex QRS tachycardias. Heart Rhythm (2010) 1.48
Standardized approaches to the investigation of syncope: Canadian Cardiovascular Society position paper. Can J Cardiol (2011) 1.47
Incidence and significance of early recurrences associated with different ablation strategies for AF: a STAR-AF substudy. J Cardiovasc Electrophysiol (2012) 1.44
Bayesian meta-analysis of genetic association studies with different sets of markers. Am J Hum Genet (2008) 1.44
Fulfilling the promise of personalized medicine? Systematic review and field synopsis of pharmacogenetic studies. PLoS One (2009) 1.43
Could NICE guidance on the choice of blood pressure lowering drugs be simplified? BMJ (2012) 1.41
Transesophageal echocardiography for the prevention of embolic complications after catheter ablation for atrial fibrillation. J Cardiovasc Electrophysiol (2009) 1.40
Utility of the NavX® Electroanatomic Mapping System for Permanent Pacemaker Implantation in a Pregnant Patient with Chagas Disease. Indian Pacing Electrophysiol J (2013) 1.40
Anticoagulation management pre- and post atrial fibrillation ablation: a survey of canadian centres. Can J Cardiol (2012) 1.39
Genetics of ischaemic stroke among persons of non-European descent: a meta-analysis of eight genes involving approximately 32,500 individuals. PLoS Med (2007) 1.38
Unintended effects of statins from observational studies in the general population: systematic review and meta-analysis. BMC Med (2014) 1.31
Influence of common genetic variation on blood lipid levels, cardiovascular risk, and coronary events in two British prospective cohort studies. Eur Heart J (2012) 1.30
Variations in cause and management of atrial fibrillation in a prospective registry of 15,400 emergency department patients in 46 countries: the RE-LY Atrial Fibrillation Registry. Circulation (2014) 1.30
Genetic variation in complement factor H and risk of coronary heart disease: eight new studies and a meta-analysis of around 48,000 individuals. Atherosclerosis (2010) 1.27
Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery. Cochrane Database Syst Rev (2013) 1.26
Chagas cardiomyopathy manifestations and Trypanosoma cruzi genotypes circulating in chronic Chagasic patients. PLoS Negl Trop Dis (2010) 1.26
Substrate and Trigger Ablation for Reduction of Atrial Fibrillation (STAR AF): a randomized, multicentre, international trial. Eur Heart J (2010) 1.25
Biomarkers of inflammation predict both vascular and non-vascular mortality in older men. Eur Heart J (2008) 1.22
Separating the mechanism-based and off-target actions of cholesteryl ester transfer protein inhibitors with CETP gene polymorphisms. Circulation (2009) 1.20
Integrated associations of genotypes with multiple blood biomarkers linked to coronary heart disease risk. Hum Mol Genet (2009) 1.17
Evaluation of adult chronic Chagas' heart disease diagnosis by molecular and serological methods. J Clin Microbiol (2009) 1.17
Ancestry as a determinant of mean population C-reactive protein values: implications for cardiovascular risk prediction. Circ Cardiovasc Genet (2010) 1.16
Towards the establishment of a consensus real-time qPCR to monitor Trypanosoma cruzi parasitemia in patients with chronic Chagas disease cardiomyopathy: a substudy from the BENEFIT trial. Acta Trop (2012) 1.16
Common variants in the HLA-DRB1-HLA-DQA1 HLA class II region are associated with susceptibility to visceral leishmaniasis. Nat Genet (2013) 1.15
2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing. Europace (2015) 1.13
Complement factor H genetic variant and age-related macular degeneration: effect size, modifiers and relationship to disease subtype. Int J Epidemiol (2012) 1.12
Interleukin-6 receptor pathways in abdominal aortic aneurysm. Eur Heart J (2012) 1.12
Does high C-reactive protein concentration increase atherosclerosis? The Whitehall II Study. PLoS One (2008) 1.09
C-reactive protein (+1444C>T) polymorphism influences CRP response following a moderate inflammatory stimulus. Atherosclerosis (2004) 1.07
UCHL-1 is not a Parkinson's disease susceptibility gene. Ann Neurol (2006) 1.06
Endothelial NO synthase genotype and risk of preeclampsia: a multicenter case-control study. Hypertension (2004) 1.04
Area-level deprivation and overall and cause-specific mortality: 12 years' observation on British women and systematic review of prospective studies. PLoS One (2013) 1.04
Acute vascular responses to isometric handgrip exercise and effects of training in persons medicated for hypertension. Am J Physiol Heart Circ Physiol (2006) 1.03
Apolipoprotein E genotype, cardiovascular biomarkers and risk of stroke: systematic review and meta-analysis of 14,015 stroke cases and pooled analysis of primary biomarker data from up to 60,883 individuals. Int J Epidemiol (2013) 1.03
Population genomics of cardiometabolic traits: design of the University College London-London School of Hygiene and Tropical Medicine-Edinburgh-Bristol (UCLEB) Consortium. PLoS One (2013) 1.02
Multilocus Bayesian meta-analysis of gene-disease associations. Am J Hum Genet (2009) 1.00
(6R)-5,6,7,8-tetrahydro-L-biopterin and its stereoisomer prevent ischemia reperfusion injury in human forearm. Arterioscler Thromb Vasc Biol (2007) 0.99
Epidemic of overweight and obesity in Latin America and the Caribbean. Int J Cardiol (2007) 0.99
Social capital, mortality, cardiovascular events and cancer: a systematic review of prospective studies. Int J Epidemiol (2014) 0.98
Pacemaker-detected atrial fibrillation in patients with pacemakers: prevalence, predictors, and current use of oral anticoagulation. Can J Cardiol (2012) 0.97
Ethnic differences in atrial fibrillation identified using implanted cardiac devices. J Cardiovasc Electrophysiol (2013) 0.97
C-reactive protein and coronary heart disease: predictive test or therapeutic target? Clin Chem (2008) 0.97
Endothelial function in patients with migraine during the interictal period. Headache (2007) 0.96
Modelling the association of disability according to the WHO International Classification of Functioning, Disability and Health (ICF) with mortality in the British Women's Heart and Health Study. J Epidemiol Community Health (2011) 0.96
Substrate and Trigger Ablation for Reduction of Atrial Fibrillation Trial-Part II (STAR AF II): design and rationale. Am Heart J (2012) 0.95
Genetic association studies in pre-eclampsia: systematic meta-analyses and field synopsis. Int J Epidemiol (2012) 0.95
Non-sustained ventricular tachycardia as a predictor of sudden cardiac death in patients with left ventricular dysfunction: a meta-analysis. Eur J Heart Fail (2008) 0.94
Predictors of patterns of change in health-related quality of life in older women over 7 years: evidence from a prospective cohort study. Age Ageing (2013) 0.94
Missing data methods in Mendelian randomization studies with multiple instruments. Am J Epidemiol (2011) 0.93
Age-dependent effect of β-blockers in preventing vasovagal syncope. Circ Arrhythm Electrophysiol (2012) 0.93
Role of the renin-angiotensin-aldosterone system in atrial fibrillation and cardiac remodeling. Curr Opin Cardiol (2005) 0.93
Safety and efficacy of dabigatran compared with warfarin for patients undergoing radiofrequency catheter ablation of atrial fibrillation: a meta-analysis. Can J Cardiol (2013) 0.92
Cardiovascular autonomic function testing in asymptomatic T. cruzi carriers: a sensitive method to identify subclinical Chagas' disease. Int J Cardiol (2004) 0.92
Frequency of eNOS polymorphisms in the Colombian general population. BMC Genet (2010) 0.91
Using waist circumference as a screening tool to identify Colombian subjects at cardiovascular risk. Eur J Cardiovasc Prev Rehabil (2003) 0.91